Treeway Goes To Phase III With ALS Oral Compound
Dutch biotech Treeway has completed its Phase I trial of lead program TW001, an oral formulation of edaravone, for the treatment of amyotrophic lateral sclerosis (ALS) and will now prepare for a pivotal Phase III study.
You may also be interested in...
The firm announced a small deal with Karyopharm for a preclinical asset with potential in ALS, but large deals are also being considered, management told the fourth quarter earnings call.
Partnered with Astellas, the San Francisco-area biotech hopes next-generation CK-107 will succeed in a measure of slow vital capacity due to stronger potency and better tolerability compared to tirasemtiv.
The arrival of the first drug for ALS in more than 20 years in the US will also be a boost to its originator Mitsubishi Tanabe's American ambitions.